Cabot Corporation — Q2 FY2024 Form 10-Q
Reporting period: Fiscal quarter and six months ended March 31, 2024. Results are unaudited and prepared under U.S. GAAP. Cabot operates through Reinforcement Materials and Performance Chemicals.
Financial performance
| Metric | Q2 FY2024 | Q2 FY2023 | Six months FY2024 | Six months FY2023 |
|---|---|---|---|---|
| Revenue | $1,019m | $1,033m | $1,977m | $1,998m |
| Gross profit | $246m | $210m | $464m | $391m |
| Operating income | $156m | $129m | $292m | $234m |
| Net income attributable to Cabot | $84m | $75m | $134m | $129m |
| Diluted EPS | $1.49 | $1.29 | $2.37 | $2.23 |
- Q2 gross margin was approximately 24.1%, compared with 20.3% a year earlier; operating margin was approximately 15.3%, versus 12.5%.
- Q2 revenue fell 1%, as lower price and product mix (a combined $61m) more than offset higher volume ($51m). Gross profit increased $36m, primarily on higher unit margins and volume.
- Q2 income before tax and equity earnings was $142m, up from $110m. The effective tax rate rose to 33% from 26%; the tax provision included $8m of net discrete tax expense.
- Cash from operations for the six months was $281m, versus $214m. Capital expenditures were $97m; investing activities used $95m. Financing activities used $195m, including $57m of share repurchases and $45m of dividends to common shareholders.
- Cash was $206m at March 31, 2024. Balance-sheet debt comprised $88m short-term borrowings, $8m current long-term debt and $1,088m long-term debt. The filing also reports $114m borrowed under the Euro credit agreement and $87m of commercial paper outstanding; investors should verify the reconciliation of these disclosures.
- Borrowing availability under credit agreements was approximately $1.1bn. Cabot said it was in compliance with debt covenants. Total current assets were $1,605m and current liabilities $718m.
Segments and changes versus prior year
- Reinforcement Materials: Q2 sales were $676m, up $4m, and segment EBIT was $149m, up $27m. Higher volumes in Asia and Europe and improved unit margins contributed to earnings growth; lower raw-material pass-through pricing reduced sales.
- Performance Chemicals: Q2 sales were $311m, down $15m, while segment EBIT rose $3m to $31m. Higher volumes partly offset lower pricing and product mix.
- For the first six months, total segment EBIT increased to $343m from $273m. Consolidated revenue declined $21m, while gross profit rose $73m. Selling and administrative expenses increased $16m for the half, primarily due to incentive compensation.
Outlook, risks and unusual items
- For Q3, management expects Reinforcement Materials EBIT to be in line with Q2: modest volume improvement is expected to be offset by higher plant-maintenance costs. Performance Chemicals is expected to have seasonally higher volumes and relatively stable unit margins.
- Management expects a FY2024 operating tax rate of 27%–29% and capital expenditures of $250m–$275m. It expects available cash, operating cash flow and credit facilities to be sufficient for obligations and investment needs over the next 12 months and foreseeable future. No overall earnings guidance is stated in the provided filing text.
- Argentina-related currency devaluation and other losses were $41m for the six months, including a $33m loss related to the December 2023 devaluation. Cabot also recorded an $8m loss on BOPREAL bonds sold to fund foreign payables. Argentina currency controls and changing rules may affect cash transfers and supplier payments; the reported outstanding legacy payables were settled in April 2024.
- Cabot began restructuring in China and Germany: it closed a reinforcing carbons unit in Tianjin and temporarily idled its Frankfurt aerogel plant while continuing commercialization efforts. Six-month charges were $12m; approximately $1m of additional charges were expected in the rest of FY2024.
- The Sarnia, Ontario plant is out of compliance with a new sulfur-dioxide air standard. Cabot is discussing an alternative with regulators; the filing anticipates significant costs for pollution controls, with installation in its current expected form by July 1, 2028. The matter had not restricted operations as of the filing.
- Respirator-claim reserves were $37m at March 31. The company says claims could change materially in the near term as underlying assumptions, insurance recoveries, other parties’ contributions or legal outcomes change. Other litigation and tax audits also remain possible sources of future expense.
- Foreign-exchange movements, raw-material and energy costs, demand, competition, customer and joint-venture relationships, project execution, regulation and geopolitical developments are among the risks identified. Management reported disclosure controls were effective and no material change in internal controls during the quarter.
Important facts for investors to verify
- Reconcile the disclosed balance-sheet short-term borrowings with the separate Euro borrowing and commercial-paper amounts.
- Track whether higher segment margins and volumes persist as raw-material costs, pricing and product mix change.
- Monitor Argentina currency restrictions, foreign-payable settlement and any further currency-related losses.
- Assess expected Sarnia emissions-control spending, timing and regulatory outcome, alongside the FY2024 capital-spending plan.
- Review developments in respirator claims and tax audits, including potential changes to reserves and cash outlays.